Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients
Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients
复制标题
DOI：
10.1002/ijc.21235
复制
发表时间：
2005-12-20
影响因子：
6.4
通讯作者：
Lehmann, K
中科院分区：
文献类型：
--
作者：
Kasper, G;Weiser, AA;Lehmann, K
我们研究了乳腺癌相关基因LIV-1的表达模式的所有和蛋白质水平在111人乳腺癌患者的原位杂交以及免疫组化，并集中在未知的潜在的LIV-1表达水平作为预后标志物。据我们所知，这是第一个内源性LIV-1蛋白表达的研究。我们的研究结果表明，LIV-1的mRNA和蛋白质的表达水平只有微弱的相关性，这表明转录后调控机制。此外，根据无复发生存期（RFS）的预后意义，LIV-1 mRNA量与阳性ER状态的组合似乎代表了比孕酮受体状态更好的标志物。LIV-1蛋白水平与肿瘤大小、分级和分期呈负相关，反映了LIV-1蛋白表达与侵袭性较低的肿瘤相关。高LIV-1蛋白表达似乎与乳腺癌浸润性导管癌患者较长的无复发生存期和总生存期相关。然而，这种关联似乎依赖于其他预后标志物。我们的数据表明，LIV-1是一个有前途的候选人，为乳腺癌患者的一种新的标志物，具有更好的结果。此外，我们的研究提出了一个修订的cDNA序列的LIV-1，并证明了本地化的内源性LIV-1的内质网。（本文的补充材料可以在国际癌症杂志网站http://www.interscience上找到。wiley.com/jpages/0020-7136/suppmat/index.html). (c)2005 Wiley-Liss，Inc.
We investigated the expression pattern of the breast cancer associated gene LIV-1 on all and protein level in 111 human breast cancer patients by in situ hybridization as well as immunohistochemistry and focused on the unknown potential of LIV-1 expression levels as a prognostic marker. To our knowledge, this is the first study on endogenous LIV-1 protein expression. Results of our study indicate that LIV-1 mRNA and protein expression levels are only weakly correlated, suggesting posttranscriptional regulatory mechanisms. Furthermore, LIV-1 mRNA quantity in combination with a positive ER status seem to represent a better marker than the progesterone receptor status according to the prognostic significance for relapse free survival (RFS). A negative correlation of LIV-1 protein levels with tumor size, grade and stage reflects an association of LIV-1 protein expression with less aggressive tumors. High LIV-1 protein expression seems to be associated with a longer relapse free and overall survival in breast cancer patients with invasive ductal carcinoma. This association, however, seems to be dependent from other prognostic markers. Our data suggest that LIV-1 is a promising candidate for a novel marker for breast cancer patients with better outcome. Furthermore, our study presents a revised cDNA sequence of LIV-1 and demonstrates the localization of endogenous LIV-1 in the endoplasmic reticulum. (Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience. wiley.com/jpages/0020-7136/suppmat/index.html). (c) 2005 Wiley-Liss, Inc.